Photochemical inactivation of chikungunya virus in plasma and platelets using the Mirasol pathogen reduction technology system

被引:42
作者
Vanlandingham, Dana L.
Keil, Shawn D. [1 ]
Horne, Kate McElroy
Pyles, Richard
Goodrich, Raymond P.
Higgs, Stephen
机构
[1] CaridianBCT Biotechnol, Lakewood, CO 80215 USA
关键词
APHERESIS PLATELETS; RIBOFLAVIN; LIGHT; TRANSFUSION; EPIDEMIC; RISK;
D O I
10.1111/j.1537-2995.2012.03717.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BACKGROUND: Chikungunya virus (CHIKV) is a reemerging mosquito-borne virus that has been responsible for a number of large-scale epidemics as well as imported cases covering a wide geographical range. As a blood-borne virus capable of mounting a high-titer viremia in infected humans, CHIKV was included on a list of risk agents for transfusion and organ transplant by the AABB Transfusion-Transmitted Diseases Committee. Therefore, we evaluated the ability of the Mirasol pathogen reduction technology (PRT) system (CaridianBCT Biotechnologies) to inactivate live virus in contaminated plasma and platelet (PLT) samples. STUDY DESIGN AND METHODS: Plasma, PLTs, and phosphate-buffered saline controls were spiked with CHIKV and treated with riboflavin and varying doses of ultraviolet (UV) light using the Mirasol PRT system. Samples were tested before and after treatment for cytotoxicity, interference, and virus titer by titration and quantitative real-time reverse transcriptionpolymerase chain reaction. RESULTS: A significant reduction in CHIKV titer of greater than 99% was recorded after treatment of plasma or PLTs with the Mirasol PRT system, and the titer reduction was directly proportional to the UV dose delivered to the samples. No cytotoxicity of interference was observed in any sample at any treatment dose. CONCLUSION: These data indicate that the Mirasol PRT system efficiently inactivated live CHIKV in plasma and PLTs and could therefore potentially be used to prevent CHIKV transmission through the blood supply.
引用
收藏
页码:284 / 290
页数:7
相关论文
共 50 条
  • [21] Bacterial inactivation of platelet concentrates with the THERAFLEX UV-Platelets pathogen inactivation system
    Gravemann, Ute
    Handke, Wiebke
    Mueller, Thomas H.
    Seltsam, Axel
    TRANSFUSION, 2019, 59 (04) : 1324 - 1332
  • [22] Cost-effectiveness of pathogen reduction technology for plasma and platelets in Quebec: A focus on potential emerging pathogens
    Gregoire, Yves
    Delage, Gilles
    Custer, Brian
    Rochette, Samuel
    Renaud, Christian
    Lewin, Antoine
    Germain, Marc
    TRANSFUSION, 2022, 62 (06) : 1208 - 1217
  • [23] A comprehensive proteomics study on platelet concentrates: Platelet proteome, storage time and Mirasol pathogen reduction technology
    Salunkhe, Vishal
    De Cuyper, Iris M.
    Papadopoulos, Petros
    van der Meer, Pieter F.
    Daal, Brunette B.
    Villa-Fajardo, Maria
    de Korte, Dirk
    van den Berg, Timo K.
    Gutierrez, Laura
    PLATELETS, 2019, 30 (03) : 368 - 379
  • [24] Pathogen inactivation of platelets using ultravioletC light: effect on in vitro function and recovery and survival of platelets
    Bashir, Saber
    Cookson, Philip
    Wiltshire, Michael
    Hawkins, Louise
    Sonoda, Luke
    Thomas, Stephen
    Seltsam, Axel
    Tolksdorf, Frank
    Williamson, Lorna M.
    Cardigan, Rebecca
    TRANSFUSION, 2013, 53 (05) : 990 - 1000
  • [25] Inactivation and Removal of Chikungunya Virus and Mayaro Virus from Plasma-derived Medicinal Products
    Yue, Constanze
    Teitz, Sebastian
    Miyabashi, Tomoyuki
    Boller, Klaus
    Lewis-Ximenez, Lia Laura
    Baylis, Sally A.
    Bluemel, Johannes
    VIRUSES-BASEL, 2019, 11 (03):
  • [26] In vitro cell quality of buffy coat platelets in additive solution treated with pathogen reduction technology
    Ostrowski, Sisse R.
    Bochsen, Louise
    Salado-Jimena, Jose A.
    Ullum, Henrik
    Reynaerts, Inge
    Goodrich, Raymond P.
    Johansson, Par I.
    TRANSFUSION, 2010, 50 (10) : 2210 - 2219
  • [27] Update on pathogen reduction technology for therapeutic plasma: An overview
    Solheim, B. G.
    Seghatchian, J.
    TRANSFUSION AND APHERESIS SCIENCE, 2006, 35 (01) : 83 - 90
  • [28] Establishment of culture systems for Genotypes 3 and 4 hepatitis E virus (HEV) obtained from human blood and application of HEV inactivation using a pathogen reduction technology system
    Owada, Takashi
    Kaneko, Moe
    Matsumoto, Chieko
    Sobata, Rieko
    Igarashi, Masashi
    Suzuki, Ko
    Matsubayashi, Keiji
    Mio, Kazuhiro
    Uchida, Shigeharu
    Satake, Masahiro
    Tadokoro, Kenji
    TRANSFUSION, 2014, 54 (11) : 2820 - 2827
  • [29] Treatment of Platelet Concentrates with the Mirasol Pathogen Inactivation System Modulates Platelet Oxidative Stress and NF-κB Activation
    Johnson, Lacey
    Marks, Denese
    TRANSFUSION MEDICINE AND HEMOTHERAPY, 2015, 42 (03) : 169 - 175
  • [30] Cell integrity and mitochondrial function after Mirasol-PRT treatment for pathogen reduction of apheresis-derived platelets: Results of a three-arm in vitro study
    Picker, Susanne M.
    Steisel, Alexander
    Gathof, Birgit S.
    TRANSFUSION AND APHERESIS SCIENCE, 2009, 40 (02) : 79 - 85